AU2020346455B2 - Drug delivery formulations - Google Patents

Drug delivery formulations Download PDF

Info

Publication number
AU2020346455B2
AU2020346455B2 AU2020346455A AU2020346455A AU2020346455B2 AU 2020346455 B2 AU2020346455 B2 AU 2020346455B2 AU 2020346455 A AU2020346455 A AU 2020346455A AU 2020346455 A AU2020346455 A AU 2020346455A AU 2020346455 B2 AU2020346455 B2 AU 2020346455B2
Authority
AU
Australia
Prior art keywords
formulation
risperidone
poly
copolymer
biodegradable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020346455A
Other languages
English (en)
Other versions
AU2020346455A1 (en
Inventor
Eran HARARY
Anthony RECH
Christophe ROBERGE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedinCell SA
Original Assignee
MedinCell SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedinCell SA filed Critical MedinCell SA
Publication of AU2020346455A1 publication Critical patent/AU2020346455A1/en
Application granted granted Critical
Publication of AU2020346455B2 publication Critical patent/AU2020346455B2/en
Priority to AU2025242078A priority Critical patent/AU2025242078A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
AU2020346455A 2019-09-13 2020-09-11 Drug delivery formulations Active AU2020346455B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025242078A AU2025242078A1 (en) 2019-09-13 2025-09-30 Drug delivery formulations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962900061P 2019-09-13 2019-09-13
US62/900,061 2019-09-13
PCT/IB2020/058474 WO2021048817A1 (en) 2019-09-13 2020-09-11 Drug delivery formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025242078A Division AU2025242078A1 (en) 2019-09-13 2025-09-30 Drug delivery formulations

Publications (2)

Publication Number Publication Date
AU2020346455A1 AU2020346455A1 (en) 2022-03-31
AU2020346455B2 true AU2020346455B2 (en) 2025-07-03

Family

ID=72521677

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020346455A Active AU2020346455B2 (en) 2019-09-13 2020-09-11 Drug delivery formulations
AU2025242078A Pending AU2025242078A1 (en) 2019-09-13 2025-09-30 Drug delivery formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025242078A Pending AU2025242078A1 (en) 2019-09-13 2025-09-30 Drug delivery formulations

Country Status (19)

Country Link
US (3) US12383493B2 (OSRAM)
EP (2) EP4027973B8 (OSRAM)
JP (2) JP7661312B2 (OSRAM)
KR (1) KR20220062372A (OSRAM)
CN (1) CN114727946A (OSRAM)
AU (2) AU2020346455B2 (OSRAM)
BR (1) BR112022004535A2 (OSRAM)
CA (1) CA3153793A1 (OSRAM)
DK (1) DK4027973T3 (OSRAM)
ES (1) ES3058225T3 (OSRAM)
FI (1) FI4027973T3 (OSRAM)
HR (1) HRP20251690T1 (OSRAM)
IL (1) IL291283A (OSRAM)
LT (1) LT4027973T (OSRAM)
MX (1) MX2022003051A (OSRAM)
PL (1) PL4027973T3 (OSRAM)
PT (1) PT4027973T (OSRAM)
SI (1) SI4027973T1 (OSRAM)
WO (1) WO2021048817A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023018652A2 (pt) * 2021-03-17 2023-10-03 Medincell S A Formulação injetável de ação prolongada compreendendo risperidona e polímeros biodegradáveis
PE20252752A1 (es) * 2023-01-10 2025-12-05 Medincell Sa Composiciones de olanzapina y metodos de uso
WO2026013080A1 (en) 2024-07-08 2026-01-15 InnoCore Technologies Holding B.V. Pharmaceutical composition based on biodegradable polymers comprising polyoxazoline

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120172454A1 (en) * 2010-12-29 2012-07-05 Medincell Biodegradable drug delivery compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1024790A4 (en) 1997-08-08 2000-10-25 Univ Utah Res Found INJECTABLE BIODEGRADABLE BLOCK COPOLYMER GELS FOR USE IN DRUG ADMINISTRATION
CA2474968A1 (en) 2002-01-31 2003-08-07 Asahi Techno Glass Corporation Cryopreservation medium for primate embryo stem cells and cryopreservation method
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
AU2009298637B2 (en) 2008-09-30 2015-08-13 Braeburn Pharmaceuticals, Inc. Implantable device for the delivery of risperidone and methods of use thereof
CN101584652B (zh) * 2009-06-19 2012-06-20 上海医药集团股份有限公司 利培酮缓释凝胶注射剂及其制备方法
EP2770983B1 (en) * 2011-10-24 2017-04-19 Braeburn Pharmaceuticals, Inc. Implantable drug delivery compositions and methods of treatment thereof
JP6134788B2 (ja) * 2012-06-27 2017-05-24 メドインセルル 疎水性組成物のための生分解性薬物送達
EP2986278A1 (en) 2013-03-11 2016-02-24 DURECT Corporation Injectable controlled release composition comprising high viscosity liquid carrier
ES3015765T3 (en) 2017-07-17 2025-05-07 Medincell S A Pharmaceutical composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120172454A1 (en) * 2010-12-29 2012-07-05 Medincell Biodegradable drug delivery compositions

Also Published As

Publication number Publication date
EP4027973B1 (en) 2025-11-05
IL291283A (en) 2022-05-01
US12383493B2 (en) 2025-08-12
EP4027973A1 (en) 2022-07-20
BR112022004535A2 (pt) 2022-06-07
ES3058225T3 (en) 2026-03-09
US20240156722A1 (en) 2024-05-16
LT4027973T (lt) 2026-01-26
US20250268817A1 (en) 2025-08-28
CA3153793A1 (en) 2021-03-18
US20220331240A1 (en) 2022-10-20
JP7661312B2 (ja) 2025-04-14
PL4027973T3 (pl) 2026-03-09
AU2025242078A1 (en) 2025-10-23
CN114727946A (zh) 2022-07-08
MX2022003051A (es) 2022-06-14
SI4027973T1 (sl) 2026-02-27
DK4027973T3 (da) 2026-01-12
PT4027973T (pt) 2026-01-05
JP2025106353A (ja) 2025-07-15
EP4706658A2 (en) 2026-03-11
AU2020346455A1 (en) 2022-03-31
FI4027973T3 (fi) 2026-01-14
HRP20251690T1 (hr) 2026-02-13
JP2022548616A (ja) 2022-11-21
EP4027973B8 (en) 2025-12-17
WO2021048817A1 (en) 2021-03-18
KR20220062372A (ko) 2022-05-16
US12128132B2 (en) 2024-10-29

Similar Documents

Publication Publication Date Title
US20250268817A1 (en) Drug delivery formulations
JP6356873B2 (ja) タキサン系活性成分含有液体組成物及び液体製剤
AU2012289968B2 (en) Stable anti-inflammatory solutions for injection
JP2007515425A (ja) 医薬組成物
JP5872551B2 (ja) パラセタモールを含む医薬組成物およびその製造法
US12329851B2 (en) Long acting injectable formulation comprising risperidone and biodegradable polymers
AU2011273064A1 (en) Pharmaceutical compositions comprising paracetamol and process for preparing the same
EP2709600A1 (en) Pharmaceutical composition comprising fexofenadine
BR122025009310A2 (pt) Formulações de entrega de fármaco
WO2021033145A1 (en) Novel injectable formulations of artesunate
CN116997323A (zh) 包含利培酮和可生物降解的聚合物的长效可注射制剂
ITMI20121154A1 (it) Soluzione iniettabile di acetaminofene per la somministrazione spinale
OA19944A (en) Pharmaceutical composition comprising fexofenadine.
AU2012260992A1 (en) Pharmaceutical composition comprising fexofenadine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)